Braunstein Zachary, Ruiz Miguel, Hanel Walter, Shindiapina Polina, Reneau John C, Brammer Jonathan E
Wexner Medical Center, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
James Comprehensive Cancer Center, Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
J Pers Med. 2022 Jun 13;12(6):964. doi: 10.3390/jpm12060964.
Peripheral T-cell lymphomas (PTCLs) are a group of heterogeneous lymphomas with poor overall prognosis, particularly in the setting of relapsed/refractory PTCL. Given the limited efficacy of current therapies, several different novel therapies encompassing multiple different mechanisms of action have been evaluated for relapsed and refractory PTCLs. In this review, we explore the current standard of care for relapsed/refractory PTCL, and evaluate in depth novel and emerging therapies, their scientific basis, and current trials for relapsed/refractory PTCL.
外周T细胞淋巴瘤（PTCL）是一组异质性淋巴瘤，总体预后较差，尤其是在复发/难治性PTCL的情况下。鉴于当前治疗方法的疗效有限，已经对几种具有多种不同作用机制的新型疗法进行了评估，用于治疗复发和难治性PTCL。在本综述中，我们探讨了复发/难治性PTCL的当前治疗标准，并深入评估了新型和新兴疗法、它们的科学依据以及复发/难治性PTCL的当前试验。
